6-(Thiophen-2-yl)-4-(4-(vinylsulfonyl)piperazin-1-yl)-thieno[2,3-d]pyrimidine

ID: ALA4849886

PubChem CID: 164611630

Max Phase: Preclinical

Molecular Formula: C16H16N4O2S3

Molecular Weight: 392.53

Molecule Type: Unknown

This compound is available for customization.

Associated Items:

Names and Identifiers

Canonical SMILES:  C=CS(=O)(=O)N1CCN(c2ncnc3sc(-c4cccs4)cc23)CC1

Standard InChI:  InChI=1S/C16H16N4O2S3/c1-2-25(21,22)20-7-5-19(6-8-20)15-12-10-14(13-4-3-9-23-13)24-16(12)18-11-17-15/h2-4,9-11H,1,5-8H2

Standard InChI Key:  XCKHJBCACLWLQY-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 25 28  0  0  0  0  0  0  0  0999 V2000
   23.3601  -22.8855    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   24.1814  -22.8855    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   23.7687  -22.1736    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   24.1814  -23.7068    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   23.4757  -24.1195    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.4757  -24.9408    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.1851  -25.3494    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   24.8945  -24.9408    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.8945  -24.1195    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.1851  -26.1699    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.4712  -26.5779    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   23.4712  -27.3985    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.1832  -27.8120    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   24.8942  -27.3927    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.8942  -26.5757    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.6697  -26.3190    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.1523  -26.9773    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.6791  -27.6384    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   26.9705  -26.9773    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.8969  -22.4728    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.8969  -21.6514    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.4509  -27.6353    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   28.2291  -27.3824    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.2291  -26.5642    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.4509  -26.3114    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  2  0
  3  2  2  0
  4  2  1  0
  5  4  1  0
  5  6  1  0
  6  7  1  0
  7  8  1  0
  8  9  1  0
  9  4  1  0
  7 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 15 14  2  0
 15 10  1  0
 16 15  1  0
 17 16  2  0
 18 17  1  0
 14 18  1  0
 17 19  1  0
  2 20  1  0
 20 21  2  0
 19 22  1  0
 22 23  1  0
 23 24  2  0
 24 25  1  0
 25 19  2  0
M  END

Alternative Forms

  1. Parent:

    ALA4849886

    ---

Associated Targets(Human)

FLT4 Tclin Vascular endothelial growth factor receptor 3 (3216 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MDA-MB-231 (73002 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MDA-MB-436 (532 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 392.53Molecular Weight (Monoisotopic): 392.0435AlogP: 3.02#Rotatable Bonds: 4
Polar Surface Area: 66.40Molecular Species: NEUTRALHBA: 7HBD:
#RO5 Violations: HBA (Lipinski): 6HBD (Lipinski): #RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: 3.71CX LogP: 2.72CX LogD: 2.72
Aromatic Rings: 3Heavy Atoms: 25QED Weighted: 0.68Np Likeness Score: -2.05

References

1. Li Y, Yang G, Zhang J, Tang P, Yang C, Wang G, Chen J, Liu J, Zhang L, Ouyang L..  (2021)  Discovery, Synthesis, and Evaluation of Highly Selective Vascular Endothelial Growth Factor Receptor 3 (VEGFR3) Inhibitor for the Potential Treatment of Metastatic Triple-Negative Breast Cancer.,  64  (16.0): [PMID:34351741] [10.1021/acs.jmedchem.1c00678]

Source